NCT03843749Unknown不适用
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Objective Response Rate(ORR)
研究概览
简要总结
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients should be histologically diagnosed with metastatic colorectal cancer or postoperative recurrence; Patients with ALK mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks;
排除标准
- •Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.
研究组 & 干预措施
HER2-positive Metastatic Colorectal Cancar
Experimental
干预措施: Pyrotinib (Drug)
结局指标
主要结局
Objective Response Rate(ORR)
时间窗: up to 36 months
Evaluation of tumor burden based on RECIST criteria.
次要结局
未报告次要终点
研究者
Zhan Wang
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
Shanghai Changzheng Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerBreast Cancer InvasiveNCT04398914Shanghai Jiao Tong University School of Medicine216
招募中
2 期
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038HER2-positive Breast CancerNCT05429294First Affiliated Hospital Xi'an Jiaotong University209
招募中
1 期
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical StudyBreast CancerNCT06770296The First Affiliated Hospital with Nanjing Medical University200
Unknown
2 期
Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisHER2-positive Breast CancerBreast CancerNCT04639271Shandong Cancer Hospital and Institute100
Unknown
2 期
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerBreast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastBreast DiseasesHormone Receptor Positive TumorMetastatic Breast CancerNCT04088110Fuzhou General Hospital77